Design, Synthesis, and Biological Evaluation of Pyrazolo[3,4-d]pyrimidines Active in Vivo on the Bcr-Abl T315I Mutant-Reference-Cited by-同舟云学术

Design, Synthesis, and Biological Evaluation of Pyrazolo[3,4-d]pyrimidines Active in Vivo on the Bcr-Abl T315I Mutant

Published:2013-06-20 Issue:13 Volume:56 Page:5382-5394
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Radi Marco¹²,Tintori Cristina¹,Musumeci Francesca³,Brullo Chiara³,Zamperini Claudio¹,Dreassi Elena¹,Fallacara Anna Lucia¹⁴,Vignaroli Giulia¹,Crespan Emmanuele⁵,Zanoli Samantha⁵,Laurenzana Ilaria⁶,Filippi Irene⁷,Maga Giovanni⁵,Schenone Silvia³,Angelucci Adriano⁸,Botta Maurizio¹⁹

Affiliation:

1. Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via Aldo Moro 2, 53100 Siena, Italy

2. Dipartimento di Farmacia, Università degli Studi di Parma, Viale delle Scienze 27/A, 43124 Parma, Italy

3. Dipartimento di Farmacia, Università degli Studi di Genova, Viale Benedetto XV 3, 16132 Genova, Italy

4. Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, 00185 Roma, Italy

5. Istituto di Genetica Molecolare, IGM-CNR, Via Abbiategrasso 207, 27100 Pavia, Italy

6. Laboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), Rionero in Vulture (PZ), Italy

7. Dipartimento di Medicina Molecolare e dello Sviluppo, Università degli Studi di Siena, Via Aldo Moro 2, 53100 Siena, Italy

8. Dipartimento di Scienze Cliniche Applicate e Biotecnologiche, Università dell’Aquila Via Vetoio, 67100 Coppito, L’Aquila, Italy

9. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, BioLife Science Building, Suite 333, 1900 North 12th Street, Philadelphia, Pennsylvania 19122, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm400233w

Reference47 articles.

1. Regulation of the c-Abl and Bcr–Abl tyrosine kinases

2. The development of imatinib as a therapeutic agent for chronic myeloid leukemia

3. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management

4. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

5. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification and Biological Characterization of the Pyrazolo[3,4-d]pyrimidine Derivative SI388 Active as Src Inhibitor;Pharmaceuticals;2023-07-04

2. A comprehensive review on the indazole based derivatives as targeted anticancer agents;Journal of Molecular Structure;2023-07

3. Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme;Pharmaceutics;2023-01-30

4. Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment;Bioorganic Chemistry;2022-11

5. Anti-Survival Effect of SI306 and Its Derivatives on Human Glioblastoma Cells;Pharmaceutics;2022-07-01